Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
To investigate whether patients with chronic-phase chronic myeloid leukemia (CP-CML) who have
achieved a complete cytogenetic response (CCyR) on imatinib (IM) or nilotinib (N) can then be
treated with a combination of the tyrosine kinase inhibitor (TKI) and interferon-α2b
(PEG-IFN-a2b, [IFN]) for 2 years, subsequently have their therapy discontinued, and then
maintain a durable molecular response off all therapy. Relapse-free survival (RFS) rate 1
year after discontinuation of the TKI and IFN will be the measurement of this objective.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center